REG - Optima Health PLC - Optima Health Secures First DART License with NHS

Optima HealthAnnouncement

11/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250211:nRSK5925Wa&default-theme=true

RNS Number : 5925W  Optima Health PLC  11 February 2025

Optima Health plc

("Optima", the "Company", and, together with its subsidiaries, the "Group")

 

Optima Health Secures First License with the NHS for its Digital Assessment
Routing Tool 'DART'

 

 

LONDON, UK, 11 February 2025, Optima Health (AIM: OPT), the UK's leading
provider of technology enabled corporate health and wellbeing solutions, today
announces it has secured the first licence contract for its proprietary
Digital Assessment Routing Tool (DART) with Mersey & West Lancashire
Teaching Hospitals NHS Trust.

DART has been commissioned to support the safe and effective stratification of
care for musculoskeletal conditions following a successful four-month quality
improvement study conducted in collaboration with the Trust. The study
demonstrated positive outcomes across all measures which included patient
safety, pathway efficiency, cost savings and patient and clinician
satisfaction. The success of DART has created significant interest from other
NHS musculoskeletal services, creating a new sales pipeline for Optima Health
including application in the NHS to reduce patient waiting lists.

DART, Optima's wholly owned tool, is DTAC (Digital Technology Assessment
Criteria) certified, and is listed on the NHS Innovation Service. It's a
digital first point of contact for patients self-referring into a
musculoskeletal pathway, providing an alternative to clinician-led triage.
Taking an average of eight minutes to complete, patients are assessed and
routed to the correct type of care based on the urgency and complexity of
their symptoms, following the "Getting It Right First Time" principle shown to
improve patient outcomes and service efficiency.

DART has received significant investment and development by Optima Health,
with validation completed in association with Queen Mary University of London
leading to published papers in international peer-reviewed
journals(1,2,3,4,5).

 

Jonathan Thomas, CEO of Optima Health, commented: "We are excited to announce
this first licence today for Optima's proprietary tool, DART. Whilst the value
of this initial licence is not material in the context of the Group's overall
revenue and profits, it aligns with the Company's growth strategy to expand
into adjacent markets.  Following the successful four-month quality
improvement study, we have received significant interest from other NHS trusts
and breaking into this new market, as planned, will provide a healthy new
sales pipeline for Optima Health."

 

 

Enquiries

 

 Optima Health                                       +44(0)3300085113

 Jonathan Thomas, CEO                                media@OptimaHealth.co.uk

 Heidi Giles, CFO

 Nominated Adviser and Corporate Broker

 Panmure Liberum Limited                             +44 (0)20 3100 2000

 Emma Earl / Will Goode / Mark Rogers

 Rupert Dearden

 UK Financial PR Adviser                             optimahealth@icrinc.com

 ICR Healthcare

 Mary-Jane Elliott / Angela Gray / Lindsey Neville

 

 

About Optima Health

Optima Health is the UK's leading provider of occupational health and
wellbeing services, directly influencing and improving people's lives for 25
years. Optima Health's incredible team of professionals quickly and
effectively encapsulate client's needs, supporting organisations of all shapes
and sizes. Through tailored solutions and innovative systems, Optima Health
offers unparalleled clinical expertise to its clients. These solutions ensure
that processes are simple and allow its clients to spend more time focusing on
their employees driving a healthy, high-performing workplace. For more
information visit www.optima health.co.uk

 

 

References

1.    Lowe C, Hanuman Sing H, Browne M, Alwashmi MF, Marsh
W, Morrissey D

Usability Testing of a Digital Assessment Routing Tool: Protocol for an
Iterative Convergent Mixed Methods Study

JMIR Res Protoc 2021;10(5):e27205 DOI: 10.2196/27205
(https://url.us.m.mimecastprotect.com/s/bEfDCqxVlyT2p5mgtZfzTEAYD6?domain=doi.org)
PMID: 34003135
(https://url.us.m.mimecastprotect.com/s/r3twCrkEmzSm5vLyUzhyT4w8Wz?domain=ncbi.nlm.nih.gov)

2.    Lowe C, Browne M, Marsh W, Morrissey D

Usability Testing of a Digital Assessment Routing Tool for Musculoskeletal
Disorders: Iterative, Convergent Mixed Methods Study
J Med Internet Res 2022;24(8):e38352 DOI: 10.2196/38352
(https://url.us.m.mimecastprotect.com/s/D0N8Cv2Y8EFlD6MJczi5TQa-rG?domain=doi.org)
PMID: 36040787
(https://url.us.m.mimecastprotect.com/s/EcykCwpEKGFND1Y5SKsmTJLEyC?domain=ncbi.nlm.nih.gov)

3.    Lowe C, Hanuman Sing H, Marsh W, Morrissey
D

Validation of a Musculoskeletal Digital Assessment Routing Tool: Protocol for
a Pilot Randomized Crossover Noninferiority Trial

JMIR Res Protoc 2021;10(12):e31541
URL: https://www.researchprotocols.org/2021/12/e31541
(https://url.us.m.mimecastprotect.com/s/ZWkJCxkV2JSX2ArpFRtQTyZQYU?domain=researchprotocols.org)
  DOI: 10.2196/31541

4.    Lowe C, Sephton R, Marsh W, Morrissey D
Evaluation of a Musculoskeletal Digital Assessment Routing Tool (DART):
Crossover Noninferiority Randomized Pilot Trial

JMIR Form Res 2024;8:e56715 DOI: 10.2196/56715
(https://url.us.m.mimecastprotect.com/s/rtCVCyP69Kc4lM9GUAuRTxzV99?domain=doi.org)
PMID: 39078682
(https://url.us.m.mimecastprotect.com/s/3I41CzpB7LFr02JXIBC9T9XFGN?domain=ncbi.nlm.nih.gov)
PMCID: 11322692
(https://url.us.m.mimecastprotect.com/s/lCZuCADQM0IRvW7xCOFjTG9hFy?domain=ncbi.nlm.nih.gov)

5.    Lowe C, Atherton L, Lloyd P, Waters A, Morrissey D

Improving safety, efficiency, cost, and satisfaction across a musculoskeletal
pathway using the Digital Assessment Routing tool for triage: a quality
improvement study.

JMIR Preprints 07/10/2024:67269 2024
DOI: https://doi.org/10.2196/preprints.67269
(https://url.us.m.mimecastprotect.com/s/ro-XCBB8Pkcng4ExF7H8T2ndOC?domain=doi.org)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBCGDDIDBDGUG